---
title: "M Stanley: Outlook for 4Q26 Catalysts in China Biotech Stocks; Sector Rated \"Attractive\""
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/302823267.md"
description: "Morgan Stanley rates the China biotech sector 'Attractive' for Q4 2026, highlighting potential catalysts. Key views include: AKESO's OS data may face risks from Western patient discontinuation; ABBISKO-B has upside if higher-dose efficacy exceeds targets; INNOVENT's mazdutide is expected to outperform semaglutide in weight loss; KEYMED's CM512 strategy shows promise for asthma differentiation; and INNOCARE remains cautious on TYK2 safety due to limited long-term data."
datetime: "2026-10-23T05:35:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/302823267.md)
  - [en](https://longbridge.com/en/news/302823267.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/302823267.md)
generator: "portal-rs"
---

# M Stanley: Outlook for 4Q26 Catalysts in China Biotech Stocks; Sector Rated "Attractive"

Morgan Stanley published a research report on China biotech stocks, identifying and previewing potential catalysts that may affect sector share prices in 4Q26. The sector is rated "Attractive".

Regarding AKESO (09926.HK) +2.500 (+2.980%) Short selling $178.97M; Ratio 31.708% , the broker expects the progression-free survival (PFS) benefit in HARMONi-3 may weaken slightly, but treatment discontinuation among Western patients and the use of pembrolizumab in the control group may create overall survival (OS) risks. Two US key opinion leaders (KOLs) expect the OS hazard ratio to reach 0.70 to 0.75, while another believes 0.78 to 0.80 would already be meaningful.

Regarding ABBISKO-B (02256.HK) -0.175 (-2.488%) Short selling $296.89K; Ratio 24.231% , if the annualized height velocity of higher-dose ABSK061 exceeds the preliminary 2.4 centimeters per year, while phosphate and corneal toxicity remain low, the broker sees upside potential.

Regarding INNOVENT BIO (01801.HK) +1.600 (+1.961%) Short selling $237.48M; Ratio 28.026% , the broker expects mazdutide to outperform semaglutide in weight reduction and liver fat improvement, though the advantages must be sufficient to justify greater gastrointestinal discomfort.

Regarding KEYMED BIO-B (02162.HK) +2.200 (+2.781%) Short selling $18.93M; Ratio 17.964% , the broker is positive on CM512's once-every-24-weeks nasal polyp strategy. If lung function improvement between doses can be sustained, it would strengthen its differentiation in asthma treatment.

Regarding INNOCARE (09969.HK) -0.120 (-1.021%) Short selling $6.06M; Ratio 19.309% , the success of Phase III trials for ICP-332 is already widely known. In the absence of longer-term infection and blood cell count data, the broker remains cautious on the safety premium of TYK2.(su/ad)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-10-23 12:25.)

### Related Stocks

- [01801.HK](https://longbridge.com/en/quote/01801.HK.md)
- [02162.HK](https://longbridge.com/en/quote/02162.HK.md)
- [02256.HK](https://longbridge.com/en/quote/02256.HK.md)
- [09926.HK](https://longbridge.com/en/quote/09926.HK.md)
- [09969.HK](https://longbridge.com/en/quote/09969.HK.md)
- [688428.CN](https://longbridge.com/en/quote/688428.CN.md)
- [MS.US](https://longbridge.com/en/quote/MS.US.md)

## Related News & Research

- [Akeso Trustee Purchases Approximately 200,000 Shares](https://longbridge.com/en/news/306120245.md)
- [Akeso Says FDA Complete Response Letter May Explain Unusual Share Price Moves](https://longbridge.com/en/news/305612661.md)
- [Akeso Announces Trustee Purchase of 200,000 Shares](https://longbridge.com/en/news/305977146.md)
- [Innovent adds seven products to China’s 2026 NRDL](https://longbridge.com/en/news/305580225.md)
- [Akeso's Gumokimab Wins China Approval for Active Ankylosing Spondylitis](https://longbridge.com/en/news/305622467.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**